Literature DB >> 17559384

The long-term efficacy of Helicobacter pylori eradication therapy in patients with idiopathic thrombocytopenic purpura.

Masaaki Satake1, Jun Nishikawa, Yuki Fukagawa, Keiko Akashi, Takeshi Okamoto, Tomoharu Yoshida, Atsuyoshi Hirano, Noboru Maetani, Youzou Iida, Isao Sakaida.   

Abstract

BACKGROUND AND AIM: A beneficial effect of Helicobacter pylori (H. pylori) eradication in patients with H. pylori-positive idiopathic thrombocytopenic purpura (ITP) has been reported by several investigators; however, it was not clear whether the recovered platelet count after H. pylori eradication was maintained for a long period.
METHOD: Thirty-eight ITP patients who were examined for H. pylori infection were assessed. H. pylori-positive patients received a standard antibiotic therapy for H. pylori eradication. We investigated the long-term effect of H. pylori eradication on platelet recovery in patients with H. pylori-positive ITP.
RESULTS: Of the 38 ITP patients, 26 (68.4%) were positive for H. pylori. The response rate of platelet recovery was 56.5% (13/23 patients). Twelve patients showed complete response (CR) and one showed partial response (PR). The mean platelet counts 6 months after eradication significantly increased from 31 x 10(9)/L to 129 x 10(9)/L in 23 H. pylori-eradicated patients (P < 0.001). The median platelet counts of responders 1, 2, 3, and 4 years after eradication were 168 x 10(9)/L (n = 10), 193 x 10(9)/L (n = 9), 168 x 10(9)/L (n = 7), and 243 x 10(9)/L (n = 4) after a mean follow-up of 25.8 months.
CONCLUSION: Eradication therapy for H. pylori-positive patients with ITP was effective and a favorable effect was maintained for long periods.

Entities:  

Mesh:

Year:  2007        PMID: 17559384     DOI: 10.1111/j.1440-1746.2007.04845.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

Review 1.  Helicobacter pylori Eradication in Patients with Immune Thrombocytopenic Purpura: A Review and the Role of Biogeography.

Authors:  Galit H Frydman; Nick Davis; Paul L Beck; James G Fox
Journal:  Helicobacter       Date:  2015-03-01       Impact factor: 5.753

Review 2.  Hematologic manifestations of Helicobacter pylori infection.

Authors:  Germán Campuzano-Maya
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

3.  Development of corpus atrophic gastritis may be associated with Helicobacter pylori-related idiopathic thrombocytopenic purpura.

Authors:  Ryugo Sato; Kazunari Murakami; Tadayoshi Okimoto; Koichiro Watanabe; Masaaki Kodama; Toshio Fujioka
Journal:  J Gastroenterol       Date:  2011-05-19       Impact factor: 7.527

Review 4.  Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence.

Authors:  Yuko Akazawa; Daisuke Fukuda; Yutaka Fukuda
Journal:  Therap Adv Gastroenterol       Date:  2016-09-22       Impact factor: 4.409

5.  Sequential eradication of Helicobacter pylori as a treatment for immune thrombocytopenia in patients with moderate thrombocytopenia: a multicenter prospective randomized phase 3 study.

Authors:  Boram Han; Hyo Jung Kim; Ho-Young Yhim; Doyeun Oh; Sung Hwa Bae; Ho-Jin Shin; Won-Sik Lee; JiHyun Kwon; Jeong-Ok Lee; Hwa Jung Kim; Soo-Mee Bang
Journal:  Ann Hematol       Date:  2022-05-28       Impact factor: 3.673

Review 6.  Efficacy of Vonoprazan for Helicobacter pylori Eradication.

Authors:  Shu Kiyotoki; Jun Nishikawa; Isao Sakaida
Journal:  Intern Med       Date:  2019-06-27       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.